아키모토 마사유키

연구 테마 및 키워드

항염증제 대사, 약물 간 상호 작용 후발 의약품의 제품 평가 연구

주요 성과

1.Hori S., Kawata T., Kogure S., Yabu S., Mori K., and Akimoto M.*, Comparative release studies on suppositories using the basket, paddle, dialysis tubing and flow-through cell methods I. Acetaminophen in a lipophilic base suppository. Pharm Dev Technol. 2017 Feb;22(1):130-135.
2. Mori K., Hori S., Kawata T., Kogure S., Matsumoto k., Hasegawa T., Akimoto M.*, The in Vitro Release of Indomethacin from Suppositories: Effects of Bases and Comparison of Different Dissolution Methods. Chem Pharm Bull., 2017;65(7):674-677
3.Matsumoto K., Hasegawa T., Ohara K., Takei C., Akimoto M.*, Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid , an active metabolite of the prodrug nabumetone. J. Pharm. Investig., 50, 71-79 (2020).
4.Matsumoto K., Hasegawa T., Ohara K., Takei C., Kamei T., Koyanagi J., Takahashi T., Akimoto M.*, A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6- methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes. Xenobiotica 50, 783-792 (2020).
5.Matsumoto K., Hasegawa T., Ohara K., Kamei T., Koyanagi J., Akimoto M*., Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro. Xenobiotica 51, 155-166 (2021).
6. Shibata Y., Ohara K., Matsumoto K., Hasegawa T., Akimoto M.*, Total Anthocyanin Content, Total Phenolic Content, and Antioxidant Activity of Various Blueberry Cultivars Grown in Togane, Chiba Prefecture, Japan. J. Nutr Sci. Vitaminol. 67, 201-209 (2021).

자세한 연구 실적은 이쪽

사회 공헌 활동

・ 지바 6대학 연계회의 : 위원
・ 지바 3대학 「실천 사회 약학의 확립과 발전에 기여하는 약사 교양 프로그램」：사업 책임자
・일반재단법인 지바 약제사회 검사 센터:평의원